Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics

References

• ZitvogelLKeppOSenovillaLMengerLChaputNKroemerGImmunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathwayClin Cancer Res201016123100310420421432
   PubMed Web of Science ®Google Scholar
• ZitvogelLApetohLGhiringhelliFKroemerGImmunological aspects of cancer chemotherapyNat Rev Immunol200881597318097448
   PubMed Web of Science ®Google Scholar
• LaouiDVan OvermeireEVan GinderachterJAUnsuspected allies: chemotherapy teams up with immunity to fight cancerEur J Immunol201343102538254224122755
   PubMed Web of Science ®Google Scholar
• ObeidMTesniereAGhiringhelliFCalreticulin exposure dictates the immunogenicity of cancer cell deathNat Med2006131546117187072
   PubMed Web of Science ®Google Scholar
• GhiringhelliFApetohLChemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategiesFuture Oncol20139446947223560368
   PubMed Web of Science ®Google Scholar
• HodgeJWGarnettCTFarsaciBChemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell deathInt J Cancer2013133362463623364915
   PubMed Web of Science ®Google Scholar
• GarnettCTSchlomJHodgeJWCombination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancementClin Cancer Res200814113536354418519787
   PubMed Web of Science ®Google Scholar
• ZitvogelLGalluzziLSmythMJKroemerGMechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillanceImmunity2013391748823890065
   PubMed Web of Science ®Google Scholar
• GalonJAngellHKBedognettiDMarincolaFMThe continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signaturesImmunity2013391112623890060
   PubMed Web of Science ®Google Scholar
• ChenDSMellmanIOncology meets immunology: the cancer-immunity cycleImmunity201339111023890059
   PubMed Web of Science ®Google Scholar
• AndreFDieciMVDubskyPMolecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerClin Cancer Res2013191283323258741
   PubMed Web of Science ®Google Scholar
• GhiringhelliFApetohLTesniereAActivation of the NLRP3 inflammasome in dendritic cells induces IL-1beta–dependent adaptive immunity against tumorsNat Med200915101170117819767732
   PubMed Web of Science ®Google Scholar
• KreiselDGelmanAEHigashikuboRStrain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancerCancer Res201272174311431722751136
   PubMed Web of Science ®Google Scholar
• LiuSKurzrockRToxicity of targeted therapy: implications for response and impact of genetic polymorphismsCancer Treat Rev201440788389124867380
   PubMed Web of Science ®Google Scholar
• RossCJVisscherHRassekhSRPharmacogenomics of serious adverse drug reactions in pediatric oncologyJ Popul Ther Clin Pharmacol201118e134e15121467604
   PubMedGoogle Scholar
• van KuilenburgABHaasjesJRichelDJClinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD geneClin Cancer Res20006124705471211156223
   PubMed Web of Science ®Google Scholar
• StoccoGCheokMHCrewsKRGenetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemiaClin Pharmacol Ther200985216417218685564
   PubMed Web of Science ®Google Scholar
• BeckJALloydSHafezparastMGenealogies of mouse inbred strainsNat Genet2000241232510615122
   PubMed Web of Science ®Google Scholar
• PletcherMTMcClurgPBatalovSUse of a dense single nucleotide polymorphism map for in silico mapping in the mousePLoS Biol2004212e39315534693
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]Bethesda, MDNational Institutes of Health2014 Available from: https://clinicaltrials.govAccessed September 30, 2014
   Google Scholar
• RobertsPJUsaryJEDarrDBCombined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsClin Cancer Res201218195290530322872574
   PubMed Web of Science ®Google Scholar
• Bekaii-SaabTPhelpsMALiXMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancersJ Clin Oncol201129172357236321519026
   PubMed Web of Science ®Google Scholar
• International Clinical Trials Registry Platform [homepage on the Internet]GenevaWorld Health Organization2014 Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12613001351707Accessed October 1, 2014
   Google Scholar
• BurrisHRodonJSharmaSFirst-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. 2010 ASCO Annual Meeting AbstractsJ Clin Oncol201028Suppl 153005
   Web of Science ®Google Scholar
• BanerjiUCamidgeDRVerheulHMThe first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerClin Cancer Res20101651613162320179232
   PubMed Web of Science ®Google Scholar
• BogueMAGrubbSCThe Mouse Phenome ProjectGenetica2004122717415619963
   PubMed Web of Science ®Google Scholar
• JohnsonISpenceMTThe Molecular Probes^® Handbook – A Guide to Fluorescent Probes and Labeling Technologies11th edLife Technologies Corporation2010 Available from: http://www.lifetechnologies.com/us/en/home/brands/molecular-probes.htmlAccessed July 17, 2014
   Google Scholar
• BuchserWCollinsMGaryantesTAssay Guidance Manual: Assay Development Guidelines for Image-Based High Content Screening, High Content Analysis and High Content Imaging [webpage on the Internet]Eli Lilly & Company and the National Center for Advancing Translational Sciences PMID: 225538612012 Available from: http://www.ncbi.nlm.nih.gov/books/NBK53196/Accessed July 17, 2014
   Google Scholar
• BeamAMotsinger-ReifABeyond IC50s: towards robust statistical methods for in vitro association studiesJ Pharmacogenomics Pharmacoproteomics201451100012125110614
   PubMedGoogle Scholar
• ReedDRBachmanovAATordoffMGForty mouse strain survey of body compositionPhysiol Behav200791559360017493645
   PubMed Web of Science ®Google Scholar
• MoellerMHiroseMMuellerSInbred mouse strains reveal biomarkers that are pro-longevity, antilongevity or role switchingAging Cell201413472973824862908
   PubMed Web of Science ®Google Scholar
• BrownCHavenerTMEverittLMcLeodHMotsinger-ReifAAA comparison of association methods for cytotoxicity mapping in pharmacogenomicsFront Genet201128622303380
   PubMedGoogle Scholar
• NicholsJLGladwellWVerheinKCGenome-wide association mapping of acute lung injury in neonatal inbred miceFASEB J20142862538255024571919
   PubMed Web of Science ®Google Scholar
• Mouse Phenome Database [homepage on the Internet]Flow-cytometric analysis of 11 inbred strains of mice. MPD: Jaxpheno6Bar Harbor, METhe Jackson Laboratory2014 Available from: http://phenome.jax.org/db/q?rtn=projects/details&sym=Jaxpheno6Accessed July 17, 2014
   Google Scholar
• Mouse Phenome Database [homepage on the Internet]Toxicity of anti-cancer agents in immune cells from 36 inbred mouse strains. MPD: Wiltshire4Bar Harbor, METhe Jackson Laboratory2014 Available at: http://phenome.jax.org/db/q?rtn=projects/projdet&reqprojid=524Accessed August 26, 2014
   Google Scholar
• LuSXNaIKHoweLConstruction of Multicolor Antibody Panels for the Flow Cytometric Analysis of Murine Thymic Stromal CellsBD Biosciences Application Note2009 Available from: https://www.bdbiosciences.com/documents/lsr_appnote02.pdfAccessed August 7, 2014
   Google Scholar
• An Introduction to Compensation for Multicolor Assays on Digital Flow CytometersBD Biosciences Technical Bulletin2009 Available from: http://www.bdbiosciences.com/documents/Compensation_Multicolor_TechBulletin.pdfAccessed August 7, 2014
   Google Scholar
• GraphPad SoftwareGraphPad Prism 5.0 learning guide [webpage on the Internet]La Jolla, CAGraphPad Software, Inc2007 Available from: http://www.graphpad.com/help/Prism5/Prism5Help.html?using_regression_guide_2.htmAccessed September 30, 2014
   Google Scholar
• HeuversMEAertsJGCornelissenRGroenHHoogstedenHCHegmansJPPatient-tailored modulation of the immune system may revolutionize future lung cancer treatmentBMC Cancer201212158023217146
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• BarpeDRRosaDDFroehlichPEPharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body massEur J Pharm Sci2010413–445846320688160
   PubMed Web of Science ®Google Scholar
• BengalaCDanesiRGuarneriVHigh-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding studyBone Marrow Transplant200331427528012621462
   PubMed Web of Science ®Google Scholar
• MairaSMStaufferFBrueggenJIdentification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMol Cancer Ther2008771851186318606717
   PubMed Web of Science ®Google Scholar
• BracciLSchiavoniGSistiguABelardelliFImmune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death Differ2014211152523787994
   PubMed Web of Science ®Google Scholar
• BronteVPittetMJThe spleen in local and systemic regulation of immunityImmunity201339580681824238338
   PubMed Web of Science ®Google Scholar
• FrickASuzukiOButzNChanEWiltshireTIn vitro and in vivo mouse models for pharmacogenetic studiesMethods Mol Biol2013101526327823824862
   PubMedGoogle Scholar
• HarrillAHWatkinsPBSuSMouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humansGenome Res20091991507151519416960
   PubMed Web of Science ®Google Scholar
• Fallahi-SichaniMHonarnejadSHeiserLMGrayJWSorgerPKMetrics other than potency reveal systematic variation in responses to cancer drugsNat Chem Biol201391170871424013279
   PubMed Web of Science ®Google Scholar
• Haibe-KainsBEl-HachemNBirkbakNJInconsistency in large pharmacogenomic studiesNature2013504748038939324284626
   PubMed Web of Science ®Google Scholar
• PaoliniGVLyonsRALaflinPHow desirable are your IC50s? A way to enhance screening-based decision makingJ Biomol Screen201015101183119320980692
   PubMedGoogle Scholar